Hypertrophy versus hyperplasia
Although all tissues and organs of the body are normally subject to the growth-regulating influences of functional demands, some are potentially capable of unlimited growth while others are not. This depends on whether hyperplasia of their functional units ceases prior to maturity or can continue throughout life. In the former case, further growth is limited by the extent to which hypertrophy can enhance physiological efficiency. Some of the body's most vitally essential organs (heart, brain, kidney, lung) lack the ability to make additional structural units in the adult and are therefore handicapped in compensating for the depreciations of advancing age. Theoretically, at least, other organs (glands, renewing tissues) possess unlimited powers of regeneration because they never lose the capacity (latent or expressed) for hyperplasia. There is a strategy in the way growth mechanisms have evolved. It may be significant that the so-called "hypertrophic" organs lose the capability for hyperplasia, because not to do so might jeopardize their growth regulation. If size is determined by functional demands, then the latter must not operate continuously lest growth go on without interruption and lead to overproduction of functional unit...Continue Reading
Vitamin D deficiency in early life and the potential programming of cardiovascular disease in adulthood
Brain regeneration in physiology and pathology: the immune signature driving therapeutic plasticity of neural stem cells
Size does matter: will knockout of p21(WAF1/CIP1) save the kidney by limiting compensatory renal growth?
Tissue and cellular distribution of subunit c of ATP synthase in Batten disease (neuronal ceroid-lipofuscinosis)
Beyond the '3/4-power law': variation in the intra- and interspecific scaling of metabolic rate in animals
Changes in RNA, DNA, protein contents and growth of turbot Scophthalmus maximus larvae and juveniles
A comparative study of embryonic development of Japanese quail selected for different patterns of postnatal growth
Substrate stiffness increases twitch power of neonatal cardiomyocytes in correlation with changes in myofibril structure and intracellular calcium
Protein synthesis and amino acid transport in the isolated rabbit right ventricular papillary muscle. Effect of isometric tension development
Protein synthetic activity of heart microsomes and robosomes during left ventricular hypertrophy in rabbits
The cardiac hypertrophy process. Analyses of factors determining pathological vs. physiological development
An Engineered Human Fibroblast Growth Factor-1 Derivative, TTHX1114, Ameliorates Short-term Corneal Nitrogen Mustard Injury in Rabbit Organ Cultures
Transcriptomic Changes Related to Cellular Processes with Particular Emphasis on Cell Activation in Lysosomal Storage Diseases from the Group of Mucopolysaccharidoses.
Cardiac hypertrophy in rats after supravalvular aortic constriction. I. Size and number of cardiomyocytes, endothelial and interstitial cells
Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy
Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.